Results 171 to 180 of about 908,554 (203)

NTRK fusions in colorectal cancer: clinical meaning and future perspective

Expert Opinion on Therapeutic Targets, 2021
Introduction Despite the efforts of the scientific community, the prognosis of metastatic colorectal cancer (mCRC) remains poor. Actionable gene fusions such as Neurotrophic Tropomyosin Receptor Kinases (NTRK) rearrangements are rare but might represent ...
M. Ratti, G. Grizzi, R. Passalacqua, A. Lampis, F. Cereatti, R. Grassia, J. Hahne   +6 more
semanticscholar   +3 more sources

NTRK fusions in thyroid cancer: pathology and clinical aspects.

Critical Reviews in Oncology/Hematology, 2023
Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase (NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer. NTRK fusion thyroid cancer has unique pathological features such as mixed structure, multiple nodes, lymph node metastasis, and a background of chronic lymphocytic thyroiditis.
Yanhui Ma, Qi Zhang, Kexin Zhang, Yunzi Liang, Fangbing Ren, Jingwen Zhang, C. Kan, Fang Han, Xiaodong Sun   +8 more
semanticscholar   +3 more sources

Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice

Cancer Biomarkers, 2023
BACKGROUND: Pan-TRK inhibitors Entrectinib and Larotrectinib have been recently approved as tumor-agnostic therapies in NTRK1-2-3 rearranged patients and there is therefore an urgent need to identify reliable and accessible biomarkers for capturing NTRK ...
A. Vingiani, D. Lorenzini, E. Conca, C. Volpi, D. V. Trupia, A. Gloghini, F. Perrone, E. Tamborini, G. Dagrada, L. Agnelli, I. Capone, A. Busico, G. Pruneri   +12 more
semanticscholar   +1 more source

Novel fusion sarcomas including targetable NTRK and ALK

Annals of Diagnostic Pathology, 2021
Challenging emerging entities with distinctive molecular signatures may benefit from algorithms for diagnostic work-up.Fusion sarcomas (2020-2021, during pandemic) were diagnosed by clinicoradiology, morphology, phenotype, and next-generation sequencing (NGS).Six fusion sarcomas in two males and four females involved the chest-wall, neck, or ...
Tiane, Chen, Ying, Wang, Lianna, Goetz, Zachary, Corey, Meaghan C, Dougher, Jessica D, Smith, Edward J, Fox, Andrew S, Freiberg, Donald, Flemming, Julie C, Fanburg-Smith   +9 more
openaire   +2 more sources

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature

Journal of Clinical Pathology, 2021
Aims The majority of pancreatic ductal adenocarcinomas (PDACs) harbour oncogenic mutations in KRAS with variants in TP53, CDKN2A and SMAD4 also prevalent. The presence of oncogenic fusions including NTRK fusions are rare but important to identify.
M. Allen, A. Zhang, P. Bavi, Jaesung Kim, G. Jang, D. Kelly, S. Perera, R. Denroche, F. Notta, Julie M. Wilson, A. Dodd, S. Ramotar, S. Hutchinson, S. Fischer, R. Grant, S. Gallinger, Julia Knox, G. O’Kane   +17 more
semanticscholar   +1 more source

[NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Neurotrophic tyrosine receptor kinase(NTRK)gene variants have been reported in a variety of cancer types. The prevalence of NTRK gene variants is less than 1% in many types of solid cancer. The highest NTRK gene fusions frequencies were found in secretary breast carcinoma and infantile fibrosarcoma.
Misao, Fukuda, Yoichi, Naito
openaire   +1 more source

NTRK-Fusions – A new kid on the block

Pathology - Research and Practice, 2019
The neurotrophic tyrosine receptor kinases (NTRK) play an important role in the development and function of the nervous system. Fusions involving NTRK and a wide range of genes that act as fusion partners are oncogenic and activate well-known signal transduction pathways like the MAPK-ERK pathway.
Märkl, Bruno, Hirschbühl, Klaus, Dhillon, Christine   +2 more
openaire   +2 more sources

NTRK fusion‐positive colorectal cancer in Japanese population

Pathology International, 2021
ALK, ROS1 and NTRK fusions are involved in the tumorigenesis of various organs, including colorectal cancer. This study aims to clarify the prevalence of these fusions in colorectal cancer in the Japanese population. Immunohistochemical analysis of 1012 specimens of colorectal cancer revealed two NTRK‐positive cases (0.2%) whereas no ALK‐ or ROS1 ...
Junpei Yonemaru, Taiki Hashimoto, Daisuke Takayanagi, Tomoaki Naka, Yasushi Yatabe, Yukihide Kanemitsu, Kouya Shiraishi, Shigeki Sekine   +7 more
openaire   +2 more sources

Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers

Expert Opinion on Investigational Drugs, 2021
Introduction: For patients with advanced/unresectable biliary tract cancers, cisplatin–gemcitabine combination is the standard first-line treatment. Beyond the first line, the therapeutic arsenal is limited with minimal benefit.
A. Boilève, L. Verlingue, A. Hollebecque, V. Boige, M. Ducreux, D. Malka   +5 more
semanticscholar   +1 more source

Safety of current treatment options for NTRK fusion-positive cancers

Expert Opinion on Drug Safety, 2023
Oncogenic NTRK fusions have been found in multiple cancer types affecting adults and/or children, including rare tumors with pathognomonic fusions and common cancers in which fusions are rare. The tropomyosin receptor kinase inhibitors (TRKi) larotrectinib and entrectinib are among the first agents with tissue agnostic FDA approvals for cancer ...
Adeline T, Yang, Theodore Willis, Laetsch   +1 more
openaire   +2 more sources